Clinical trials: Relapsed/Refractory
Follicular Lymphoma
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in…
- Trial name
- NCT05846763
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Colorectal Carcinoma
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
The purpose of this study is to evaluate how tumors in patients with colorectal carcinoma respond to treatment with VELCADE alone versus VELCADE given with irinotecan, and also to see what effects (good and bad) it has on you and…
- Trial name
- NCT00051987
- Testing
- VELCADE TM (bortezomib) for Injection, or PS-341
- Where
- 22 sites in United States
- Volunteers
- 175 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hodgkin Lymphoma
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP
- Trial name
- HD-R3i (NCT01453504)
- Testing
- DHAP, Everolimus
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- University of Cologne
Refractory or Relapsed Non-Hodgkin's Lymphoma
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory…
- Trial name
- CART-Omic (NCT05422521)
- Testing
- blood samples and 18FDG PET-CT exams
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
- Trial name
- NCT03299738
- Testing
- C-CAR011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai AbelZeta Ltd.
Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
RVU120 Rollover Study
This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when…
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- Trial name
- ROVER-01 (NCT06987058)
- Testing
- RVU120, Ruxolitinib
- Where
- 7 sites in France, Poland
- Volunteers
- 14 people
- Sponsor
- Ryvu Therapeutics SA
Hematologic Diseases, Neoplasms
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant…
- Trial name
- NCT05827835
- Testing
- CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more…
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002508
- Testing
- carboplatin, etoposide, autologous bone marrow transplantation
- Where
- United States
- Sponsor
- Temple University
Mantle Cell Lymphoma
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.
- Trial name
- NCT01646021
- Testing
- Ibrutinib, Temsirolimus
- Where
- 92 sites in Belgium, Brazil and 19 more
- Volunteers
- 280 people
- Sponsor
- Janssen Research & Development, LLC
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT06483048
- Testing
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Small Cell Lung Cancer
Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer
Phase II studies with docetaxel in first line - and second line treatment of SCLC demonstrated that docetaxel is an active agent in these patient groups.
- Trial name
- DOCAR (NCT00686985)
- Testing
- Carboplatin, docetaxel
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Dr. B. Biesma
Lymphoma, Large-Cell, Diffuse
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584.
- Trial name
- NCT00511043
- Testing
- PTK787
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- David Rizzieri, MD
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T…
- Trial name
- NCT03126864
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
- Trial name
- NCT05506332
- Testing
- Venetoclax, 6-mercaptopurine
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
The study objectives are to evaluate the safety and efficacy of the oral administration of lenalidomide in combination with dexamethasone in the treatment of adult patients with refractory or relapsed non-Ph+ B-cell lineage acute…
- Trial name
- RV-405 LAL (NCT01116193)
- Testing
- Lenalidomide plus dexamethasone
- Where
- 4 sites in France
- Volunteers
- 10 people
- Sponsor
- Institut de Cancérologie de la Loire
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult
Natural Killer-cell Therapy for Acute Myeloid Leukemia
This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning…
- Trial name
- NK4AML (NCT04347616)
- Testing
- UCB-NK cells, IL-2
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- Radboud University Medical Center
Acute Myeloid Leukemia With FLT3/ITD Mutation
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy.
- Trial name
- NCT05024552
- Testing
- Gilteritinib, Vyxeos
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone…
- Trial name
- DREAMM 7 (NCT04246047)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 69 sites in United States, Australia and 11 more
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline